Risk Factors for Hepatitis C Virus Transmission to Health Care Workers after Occupational Exposure

In order to decrease the incidence of occupational transmission of hepatitis C, health care professionals require access to needlestick prevention devices, according to results of a new study published in the November 15, 2005 issue of Clinical Infectious Diseases.

Researchers conducted this matched case-control study in 5 European countries from 1 January 1991 through 31 December 2002.

Case patients were health care workers who experienced seroconversion after percutaneous or mucocutaneous exposure to HCV. Control subjects were HCV-exposed health care workers who did not experience seroconversion and were matched with case patients for center and period of exposure.

Results

Sixty case patients and 204 control subjects were included in the study.

All case patients were exposed to HCV-infected fluids through percutaneous injuries.

The 37 case patients for whom information was available were exposed to viremic source patients.

As risk factors for HCV infection, multivariate analysis identified needle placement in a source patient's vein or artery, deep injury, and sex of the health care worker.

Source patient HCV load was not introduced in the multivariate model.

In unmatched univariate analysis, the risk of HCV transmission increased 11-fold for health care workers exposed to source patients with a viral load >6 log10 copies/mL, compared with exposures to source patients with a viral load </= 4 log10 copies/mL.

Conclusion

In this study, HCV occupational transmission was found to occur after percutaneous exposures. The risk of HCV transmission after percutaneous exposure increased with deep injuries and procedures involving hollow-bore needle placement in the source patient's vein or artery.

The authors conclude, “These results highlight the need for widespread adoption of needlestick-prevention devices in health care settings, together with other preventive measures.”

“Additional studies are required to identify risk factors for hepatitis C virus (HCV) transmission to health care workers after occupational exposure to HCV.”

Discussion

In addition, until new anti-HCV drugs (such as HCV serine protease inhibitors, which may eventually be used for postexposure prophylaxis) become available, the present results have important implications for the counseling and follow-up of health care workers after exposure.

They suggest that, after occupational exposure to HCV, assessment of the risk of transmission should take into account the severity of the injury, the device involved, and the HCV RNA status of the source patient.

“Following this assessment,” write the authors, “health care workers at low risk for transmission should be fully informed of this fact, because such information would, no doubt, substantially reduce the anxiety caused by their injury. Follow-up schedules based on the results of anti-HCV antibody testing could then be proposed to health care workers who are at low risk. “

Finally, they conclude, “For health care workers experiencing high-risk exposures, follow-up schedules based on alanine transaminase monitoring, as currently recommended by European guidelines, or HCV RNA testing may be proposed; if acute HCV infection is detected, adequate treatments may be initiated, although the ideal timing and regimen of antiviral therapy remain to be defined. However, these follow-up strategies and the frequency of postexposure testing need to be further investigated through well-designed cost-effectiveness studies.”

10/24/05

Reference
Y Yazdanpanah and others. Risk Factors for Hepatitis C Virus Transmission to Health Care Workers after Occupational Exposure: A European Case-Control Study. Clinical Infectious Diseases 41(10): 1423-1430. November 15, 2005.

 




All HCV Topics
 [ A to Z ]


2-log Drop
Acute (Primary) HCV Infection
Age
Alcohol / Smoking / Diabetes
ALT
Anemia
Children
Chronic HCV Infection
Cirrhosis
Cognitive Behavioral Therapy
Complementary Therapies (CAM)
Combination Treatment
Cryoglobulinemia / Cryoglobulin
Disease Progression
Decompensation
Developing Countries
Depression
Diabetes Mellitus
Dosing
Drug Abuse
Drug Pricing

Drug Related Adverse Events
Early Treatment Cessation
Early Virologic Response

Epidemiology / African Americans
Epoetin Alpha
Early Viral Response (EVR)
Eradication
Extrahepatic Events
Experimental Treatment
Experimental Therapy (procedure)
Fibrosis
Gender
Genetics
Genotype 1 and 4
Genotype 2 and 3
Genotype 5 and 6
GGT Levels
Glucose Intolerance
Growth Factors
Guidelines

HCV Clearance
HCV Disease Progression
HCV-Drug Related Adverse Events
HCV Recurrence After Transplantation
Hearing
Hematological Growth Factors
Hemodialysis
Hemoglobin
Hemophilia
Hepatic Decompensation
Hepatic Failure
Hematological Disorders
Hepatocellular Carcinoma
Histology

Hormone Therapies
hyaluronate (HA)
Immunoglobulins
Immunosuppression
Induction Therapy
Injection Drug Use
Infergen
Insulin Resistance
Interferon
Interferon Resistance
Intron A
Kidney Disorders
Kidney Transplant

Liver Biopsy
Liver Enzymes
Liver Issues
Living Donors
Liver Stiffness Measurement (LSM)
Maintenance Therapy
Methadone
Miscellaneous
Mortality and Morbidity

Monotherapy Treatment

Mother to Child Transmission of HCV
Natural History
Neutropenia
Non-Alcoholic Fatty Liver
  Disease (NAFLD)

Non-Hepatic Cancers
Non-Hodgkins Lymphoma
Non-organ Specific Autoantibodies
Nonresponders / Relapsers
Obesity
Occult HBV Infection
Pathogenesis

Pegasys
PEG-Intron
Pegylated Inferferon
Pharmacokinetics
Platelets
Pregnancy
Productivity
PIIINP/MMP-1, prothrombin time (PT)
Quality of Life
Quasispecies
Rapid Virologic Response (RVR)
Recurrent HCV
Re-Treatment
Retinopathy
Ribavirin
Ribavirin Dosing
Risk Factors for HCC
Risk Factors
Roferon
Seroconversion
Sex (gender)
Sexual Transmission
Skin Reactions / Diseases
Sleeplessness
Steatosis
Steroids
Superinfection
Survival
Sustained Viral Response
Toxicities and Side Events
Transmission

Transplantation
Undetectable HCV RNA
Viral Eradication
Viral Kinetics
Viral Load
Weight-based Dosing
Women and Children

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 


HIV AND AIDS
| HEPATITIS B | HEPATITIS C | HIV / HBV CO-INFECTION | HIV / HCV CO-INFECTION | HEALTH
|
TESTS | INTERNET CONFERENCE REPORTS | LINKS | ABOUT US | CONTACT US